standing

Analyzing Token Sale Models

Source Node:
Time Stamp: February 20, 2024 1:29 PM - Modified On: February 20, 2024 - Published By:
Source Cluster:
Republished By Plato

Note: I mention the names of various projects below only to compare and contrast their token sale mechanisms; this should NOT be taken as an endorsement or criticism of any specific project as a whole. It's entirely possible for any given project to be total trash as a whole and yet still have an awesome token sale model. The last few months have seen an increasing amount of innovation in token sale models. Two years ago, the space was simple: there were capped sales, which sold a fixed number of

Walking the Tightrope

Source Node:
Time Stamp: November 15, 2023 5:19 AM - Modified On: November 15, 2023 - Published By:
Source Cluster:
Republished By Plato

As we stand on the verge of a new era in crypto, it’s crucial to reaffirm the importance of decentralization. Beyond being a mere aspiration, decentralization serves as the lifeblood of the crypto world, standing as the pivotal force that draws the line between freedom and control. Amidst the hype surrounding the impending approval of a spot Bitcoin ETF in the United States, accompanied by the influx of capital from behemoths like BlackRock, the immediate market surge raises a serious question for the future of crypto. Are people here for

NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.

Source Node:
Time Stamp: October 24, 2023 11:55 AM - Modified On: October 24, 2023 - Published By:
Source Cluster:
Republished By Plato

Summary: Progress in Neurodegenerative Research:  NKGen’s Phase 1/2a Clinical Trial for SNK01 on Track for End-of-Year Initiation SANTA ANA, Calif., Oct. 24, 2023 (Plato / Amplifi) -- Today, NKGen Biotech Inc. (Nasdaq: NKGN), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics, proudly announced the progression of its SNK01 program targeting Alzheimer’s Disease (AD), backed by the green light from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. NKGen is gearing up to initiate its Phase 1/2a clinical trial

Embracing the True Spirit of Decentralization: Shiba Classic – Your New Haven!

Source Node:
Time Stamp: October 12, 2023 11:12 AM - Modified On: October 12, 2023 - Published By:
Source Cluster:
Republished By Plato

The idea of decentralization has taken front stage in the fast-paced world of cryptocurrencies, promising a more equitable, inclusive, and transparent financial environment. Not all projects, nevertheless, have adhered to these guidelines. Enter Shiba Classic (SHIBC), a game-changer with a team that has a track record of success taking projects from $0 to $100 million. Shiba Classic is an example of what decentralization stands for. The Shiba Classic crew is now all in and prepared to cause a stir in the DeFi community. Unveiling Shiba Classic - A True Beacon